At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 326 enrolled
Drug / intervention
125 µg Ocriplasmin +1 moredrug
Likely dose
125 µg Ocriplasminfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion
In Brief
A Phase 3 clinical trial evaluating 125 µg Ocriplasmin and Placebo for Vitreomacular Adhesion. Completed, enrolled 326 participants across 41 sites.
Detailed Summary
The objective of this trial is to evaluate the safety and efficacy of intravitreal microplasmin 125µg dose in subjects wiht focal vitreomacular adhesion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitreomacular Adhesion
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartDec 2008
Primary CompletionMar 2010
Study CompletionApr 2010
TodayJul 2026
First PostedOct 29, 2008
Enrollment StartDec 1, 2008
Primary CompletionMar 1, 2010
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.7 years ago
Interventions
125 µg Ocriplasmindrug
125µg ocriplasmin intravitreal injection
Placebodrug
Placebo intravitreal injection